Get to know our clinical trials

CLINICAL TRIAL OF RO7444973 IN PARTICIPANTS WITH UNRESECTABLE AND/OR METASTATIC MAGE A4-POSITIVE SOLID TUMORS

THE PURPOSE OF THIS STUDY IS TO TEST A NEW DRUG CALLED RO7444973 IN PATIENTS WITH SOLID TUMORS AND TO SEE IF IT HAS EFFECTS (GOOD OR BAD) ON THEIR BODY AND THEIR TUMOR, AS WELL AS TO FIND OUT WHAT HAPPENS TO RO7444973 ONCE IT IS IN THE BODY.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7444973 IN PARTICIPANTS WITH UNRESECTABLE AND/OR METASTATIC MAGE A4-POSITIVE SOLID TUMORS.
  • Code EudraCT: 2021-000624-35
  • Protocol number: BE43244
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.